Novavax, Inc. (Novavax) is a clinical-stage biopharmaceutical company. The company discovers vaccines and vaccine adjuvants that address a range of infectious diseases. They also manage a research and manufacturing facility at their headquarters in Maryland, U.S.A.

The vision of Novavax is to control the outbreak of infectious diseases by using a unique single-manufacturing system. This system allows rapid mass production of recombinant protein nanoparticle vaccines. The company thrives on their commitment to rapidly deliver customized vaccine during an outbreak.

The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology, which includes virus-like particle technology (VRS) and recombinant nanoparticle protein micelle technology. Their product portfolio includes vaccines indicated against seasonal quadrivalent influenza, pandemic (H5N1) influenza, respiratory syncytial virus (RSV), seasonal trivalent influenza, pandemic (H1N1) influenza and rabies.

The online company has established partnerships with GE Healthcare Company, LG Life Sciences, Ltd. (LGLS), the U.S. Department of Health & Human Services (HHS) BARDA (office of Biomedical Advanced Research and Development Authority) and PATH Vaccine Solutions for the development of their vaccines. They are also part of Progressive Digital Media Group PIc.

Novavax is a combination of state-of-the-art science, cutting-edge techniques and passionate, skilled professionals to create vaccines, curing the pandemic diseases in the future. They aim to provide authentic solutions by producing vaccines across the globe.